Table 1 Patient and sample overview. Each patient developed an intracranial metastasis and an extracranial metastasis in either lung, lymph node, skin, liver or soft tissue.

From: Patient-specific identification of genome-wide DNA-methylation differences between intracranial and extracranial melanoma metastases

Patient

Intracranial

metastasis

Extracranial

metastasis

Treatment

P02

1 sample

1 lymph node sample

Untreated

P03

1 sample

1 lung sample

Untreated

P04

1 sample

2 skin samples

Untreated

P06

2 samples

1 lymph node sample

IM: CTX & ITX (stopped)

P08

1 sample

3 soft tissue samples

IM, EM: CTX & ITX

P09

1 sample

1 liver sample

Untreated

P16

1 sample

1 lung sample

Untreated

P17

1 sample

2 lymph node samples

Untreated

P18

1 sample

2 lung samples

Untreated

P28

1 sample

1 skin sample

IM, EM: CTX & ITX (stopped); IM: WBRT

P39

1 sample

1 lung sample

IM, EM: ITX (stopped)

P42

1 sample

2 lymph node samples

IM: CTX

P64

1 sample

1 lung sample

Untreated

P67

2 samples

2 lung samples

Unknown

  1. Multiple samples of the same metastasis were taken if they showed histologically different regions. The treatment column provides information if and how a patient was treated before the surgical removal of a metastasis.
  2. IM Intracranial metastasis, EM Extracranial metastasis, CTX Chemotherapy, ITX Immunotherapy, WBRT Whole brain radiotherapy. Treatment of three patients was stopped at least one month before surgery. Metastases of P67 were obtained post mortem.
Back to article page